Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

The CDC will no longer recommend routine Covid-19 vaccines for healthy kids and pregnant women after HHS Secretary Robert F.

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...

Devoted Health, the Medicare Advantage insurer with a medical group, has laid off about 120 employees. The layoffs, which ...

After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

The Column Group's drug R&D team, known as TCG Labs Soleil, has been busy churning out new portfolio companies since it ...

Strand Therapeutics reports early positive data for STX-001, a self-replicating mRNA cancer therapy, showing safety and ...

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B ...